Type
|
Public |
---|---|
Traded as | NASDAQ: RBCN |
Industry | Material, sapphire substrates |
Founded | 2001 |
Website | rubicontechnology |
Rubicon Technology, Inc. is an American company specializing in sapphire crystal growth technology and large-diameter sapphire based on improved Kyropoulos technology called ES2. Improvements to the Kyropoulos technology were developed in its Illinois-based crystal growth facilities. The company has been producing the industry's first 12-inch sapphire wafer since 2010, and has shipped millions of wafers and core products in sizes from 2" to 12" since 2001. The company's markets have been focused on the LED industry and the production of silicon on sapphire (SOS) wafers for integrated circuits (RFICs), as well as on high quality optical and industrial applications for high performance sapphire. The company's current market capitalization is down from around US$ 200 million to $13 million, with an enterprise value (November 2013 to December 2016) from around US$ 160 million to less than zero.
In 2000, Rubicon Technology began its commercial production and was incorporated in 2001. It had successful growth of 30 kg sapphire boule in 2002. In 2003, its polishing capacity was added and it received ISO9001 certification in the following year. In 2013, Rubicon launched 4" and 6" Patterned Sapphire Substrates (PSS), extending vertical integration "from powder to pattern".
Rubicon Technology is engaged in developing, manufacturing and selling monocrystalline sapphire and other crystalline products for light-emitting diodes (LEDs), radio-frequency integrated circuits (RFICs), optoelectronics, and other optical applications.
Rubicon Technology produces Patterned Sapphire Substrates (PSS) in 4" through 8" diameters. The company also produces sapphire ingots, which are used as raw material for further fabrication. Additionally, Rubicon produces optical windows, with applications ranging from defense/aerospace and instrumentation to medical devices, and polished epi-ready substrates.
2016-05-11 | Reiterated Rating | Canaccord Genuity | Hold | $0.75 |
2016-02-25 | Reiterated Rating | Canaccord Genuity | Hold | $1.05 to $0.90 |
2015-11-10 | Reiterated Rating | Oppenheimer | Hold | |
2015-11-10 | Reiterated Rating | Canaccord Genuity | Hold | $1.65 to $1.05 |
2015-11-10 | Reiterated Rating | Oppenheimer Holdings Inc. | Hold | |
2015-10-15 | Reiterated Rating | Northland Securities | Market Perform | |
2015-08-07 | Reiterated Rating | Canaccord Genuity | Hold | $3.50 to $1.65 |
2015-08-07 | Reiterated Rating | Oppenheimer | Market Perform | |
2015-05-08 | Reiterated Rating | Canaccord Genuity | Hold | $3.50 |
2015-02-25 | Reiterated Rating | Needham & Company LLC | Buy | |
2015-02-13 | Reiterated Rating | Canaccord Genuity | Hold | $5.00 |
2014-11-07 | Reiterated Rating | Canaccord Genuity | Hold | $8.00 to $5.00 |
2014-11-07 | Downgrade | Dougherty & Co | Buy to Neutral | |
2014-10-13 | Reiterated Rating | Dougherty & Co | Positive | |
2014-08-08 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $13.00 to $8.00 |
2014-08-08 | Downgrade | Canaccord Genuity | Buy to Hold | $10.00 to $8.00 |
2014-07-23 | Initiated Coverage | Goldman Sachs | Sell | $6.00 |
2014-07-23 | Initiated Coverage | Goldman Sachs Group Inc. | Sell | $6.00 |
2014-06-06 | Reiterated Rating | Canaccord Genuity | Buy | $14.00 to $10.00 |
2014-05-23 | Upgrade | Oppenheimer | Underperform to Market Perform | $7.50 |
2014-05-13 | Initiated | Dougherty & Company | Buy | $11 |
2014-05-13 | Initiated Coverage | Dougherty & Co | Buy | $11.00 |
2014-05-02 | Lower Price Target | Canaccord Genuity | $15.00 to $14.00 | |
2014-04-01 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | $12.00 to $14.00 |
2014-03-28 | Reiterated | UBS | Neutral | $9.50 to $12 |
2014-03-26 | Reiterated Rating | Canaccord Genuity | Buy | $15.00 |
2014-03-18 | Boost Price Target | DA Davidson | $13.00 to $17.00 | |
2014-03-17 | Boost Price Target | DA Davidson | $13.00 to $17.00 | |
2014-03-06 | Downgrade | Summit Research | Hold to Sell | $9.50 |
2014-02-20 | Boost Price Target | JPMorgan Chase & Co. | $7.50 to $12.00 | |
2014-02-20 | Boost Price Target | Canaccord Genuity | $12.00 to $15.00 | |
2013-10-30 | Lower Price Target | Sterne Agee CRT | Buy | $18.00 to $17.00 |
2013-10-30 | Boost Price Target | Piper Jaffray | Underweight | $3.00 to $5.00 |
2013-10-30 | Lower Price Target | Oppenheimer | Underperform | $9.00 to $7.50 |
2013-10-30 | Lower Price Target | Lazard Capital Markets | Buy | $14.00 to $12.00 |
2013-10-30 | Lower Price Target | DA Davidson | Buy | $16.00 to $13.00 |
2013-10-30 | Lower Price Target | Canaccord Genuity | Buy | $15.00 to $12.00 |
2013-10-01 | Downgrade | Oppenheimer | Market Perform to Underperform | $11.65 to $9.00 |
2013-10-01 | Boost Price Target | Canaccord Genuity | Buy | $12.00 to $15.00 |
2013-02-21 | Reiterated | UBS | Neutral | $7 to $5.50 |
2012-11-07 | Downgrade | Avian | Positive to Neutral | $12 to $10 |
2012-03-14 | Upgrade | Avian | Neutral to Positive | |
2011-12-13 | Upgrade | Ticonderoga | Sell to Neutral | |
2011-11-09 | Downgrade | UBS | Buy to Neutral | $12 to $11 |
2011-11-09 | Downgrade | Avian | Positive to Neutral | |
2011-10-03 | Reiterated | Canaccord Genuity | Hold | $11 to $9 |
2011-08-05 | Reiterated | UBS | Buy | $28 to $15 |
2011-05-06 | Reiterated | UBS | Buy | $38 to $40 |
2011-04-26 | Reiterated | UBS | Buy | $30 to $38 |
2011-02-17 | Reiterated | UBS | Buy | $25.50 to $30 |
2011-02-17 | Reiterated | Kaufman Bros | Buy | $30 to $32 |
2011-01-31 | Downgrade | Canaccord Genuity | Buy to Hold | $36 to $20 |
2010-12-17 | Downgrade | Oppenheimer | Outperform to Perform | |
2010-12-01 | Initiated | Kaufman Bros | Buy | $30 |
2010-11-05 | Reiterated | UBS | Buy | $41 to $36 |
2010-10-01 | Initiated | Merriman | Sell | |
2010-06-07 | Reiterated | Oppenheimer | Outperform | $30 to $34 |
2010-05-10 | Upgrade | Oppenheimer | Perform to Outperform | $30 |
2016-05-11 | Reiterated Rating | Canaccord Genuity | Hold | $0.75 |
2016-02-25 | Reiterated Rating | Canaccord Genuity | Hold | $1.05 to $0.90 |
2015-11-10 | Reiterated Rating | Oppenheimer | Hold | |
2015-11-10 | Reiterated Rating | Canaccord Genuity | Hold | $1.65 to $1.05 |
2015-11-10 | Reiterated Rating | Oppenheimer Holdings Inc. | Hold |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In RBCN 20 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Institutional Trust Company, N.A. | 0.52M |
Bandera Partners LLC | 0.13M |
RENAISSANCE TECHNOLOGIES LLC | 90671 |
AMERIPRISE FINANCIAL INC | 35339 |
CITADEL ADVISORS LLC | 21412 |
BlackRock Inc. | 20137 |
GEODE CAPITAL MANAGEMENT, LLC | 10419 |
BlackRock Fund Advisors | 6464 |
BLACKROCK ADVISORS LLC | 5299 |
Tower Research Capital LLC (TRC) | 5237 |
MORGAN STANLEY | 3147 |
AlphaMark Advisors, LLC | 500 |
LADENBURG THALMANN FINANCIAL SERVICES INC | 375 |
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 82 |
UBS Group AG | 57 |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
CROSS ATLANTIC CAPITAL PARTNERS II INC | 8.48% (2217851) | RBCN / |
Gazelle TechVentures, Inc. | 5.98% (1564997) | RBCN / |
Spencer Raymond J | 0.56% (147551) | RBCN / |
Brog Timothy E | 0.16% (42759) | PRLS / RBCN / |
Tamim Hany Chief Operating Officer | 0.14% (36333) | RBCN / |
MIKOLAJCZYK MICHAEL E | 0.14% (36275) | RBCN / |
Parvez Raja M President, CEO & Director | 0.11% (27985) | RBCN / |
Aquilano Don N | 0.10% (26287) | RBCN / |
Cross Atlantic Capital Partners, Inc. | 0.08% (19763) | AMBR / RBCN / |
Weissman William F CFO, Treasurer and Secretary | 0.05% (14136) | RBCN / |
HUNTER GORDON | 0.03% (8900) | CTS / LFUS / RBCN / VECO / |
Graffy Mardel A VP - Financial Operations | 0.02% (4938) | RBCN / |
Westphal Susan | 0.02% (4038) | RBCN / |